Ilyang Pharmaceutical
Daily close in US$ at the latest USD/KRW close. Source: KRX via FinanceDataReader.
Ilyang Pharmaceutical makes prescription and over-the-counter medicines supplied to hospitals, clinics, and pharmacies in Korea.
The company is listed on KOSPI, Korea's main stock exchange, and operates across the broader pharmaceutical industry serving healthcare providers and patients. Because the filing text does not detail a single dominant product line or structural shift, the business is best described as a diversified domestic pharmaceutical company.
Summary is AI-generated and may contain errors · figures from DART filings
Ilyang Pharmaceutical in five facts
What does Ilyang Pharmaceutical do?
Ilyang Pharmaceutical makes prescription and over-the-counter medicines supplied to hospitals, clinics, and pharmacies in Korea.
Where is Ilyang Pharmaceutical listed and in which sector?
Ilyang Pharmaceutical (Korean name: 일양약품) trades under KRX code 007570 on KOSPI, the main board of the Korea Exchange. It is classified in the Health Care sector, Pharmaceuticals.
How large is Ilyang Pharmaceutical?
Its market capitalisation was US$101.4M on 2026-10-21, which puts it in this site's small-cap group. US$ amounts are converted from won at 1 USD ≈ ₩1,325 (2026-10-21).
What were Ilyang Pharmaceutical's latest annual revenue and operating profit?
For fiscal year 2025, Ilyang Pharmaceutical reported revenue of US$205.6M, operating profit of US$3.7M and net income of US$5.4M, per its annual report on DART (data retrieved from DART on 2026-09-08). Revenue was up 1.3% on the previous year.
Where does this data come from?
Financial statements and filings come from DART, Korea's official corporate-filing system. Share prices, market capitalisation and trading status come from KRX. Company summaries are AI-generated from the filings and may contain errors; financial figures are mapped directly from DART.
Data sources and last updated
- Filings and financial statements
- DART (dart.fss.or.kr), Korea's official corporate-filing system
- Prices, market cap, trading status
- KRX (Korea Exchange), via FinanceDataReader
- Latest annual financials
- Fiscal year 2025, data retrieved from DART on 2026-09-08
- Share price and market cap
- Close of 2026-10-21
- Currency
- US$, converted from won at 1 USD ≈ ₩1,325 (2026-10-21 close)
- Company data updated
- 2026-10-21
- Company summary
- AI-generated from filings; may contain errors. Information only, not investment advice.
- [Amended] DisclosureOct 8
- DisclosureOct 7
- Change in shares held by the largest shareholderSep 23
- Report on large shareholdings (5% rule) (standard)Sep 23
- Report on large shareholdings (5% rule) (standard)Sep 23
- Report on securities held by executives/major shareholdersSep 23
- Report on securities held by executives/major shareholdersSep 23
- Report on securities held by executives/major shareholdersSep 14
- DisclosureSep 10
- [Amended] Supply contract terminatedSupply contract · Sep 10 · 2 versions
- Change of largest shareholder
Ilyang Pharmaceutical reports a change in largest shareholder from Jeong Do-eon (and 7 others) to Jeong Yu-seok (and 7 others) via a gift of 1,700,000 shares, with the largest-shareholder group's total holdings unchanged at 5,150,673 shares (26.98%), effective July 30, 2026.
Ownership change · Jul 30 - [Amended] Decision to acquire shares/equity in another company
Ilyang Pharmaceutical updated the disclosed terms of an acquisition of Ilyang Pharmaceutical (Jilin) Co., Ltd., now worth US$11.4M.
M&A · Jun 30 · 2 versions - [Amended] Supply contract signed
Ilyang Pharmaceutical updated a previously disclosed supply contract, now worth US$8.94M, about 5.15% of its recent annual revenue, running through Jun 2026.
Supply contract · Jun 30 - Cash/in-kind dividend decision
Ilyang Pharmaceutical declared a cash dividend of US$0.11 per share.
Dividend · Feb 3 - Change of 30% or more in revenue or profit/loss structure (15% for large companies)
Ilyang Pharmaceutical reported consolidated results for FY2025: revenue of US$187M (+1.3% year on year), operating profit of US$3.25M (−53% year on year) and net income of US$4.06M (−38.7% year on year).
Earnings · Feb 3